Absci Corporation (NASDAQ:ABSI) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Announced: about US$100M · US$7.41 a share · Jefferies +3 Dealers: Jefferies (co-lead), J.P. Morgan (co-lead), TD Cowen (co-lead), Guggenheim Securities (co-lead) Buyers: Eli Lilly & Company; Adage; BVF Partners; Columbia Threadneedle; Invus; Redmile Use of proceeds: Advance ABS-201 anti-PRLR antibody in androgenetic alopecia and endometriosis, plus working capital and general corporate purposes | Jun 24, 2026 |
| Public offering of common stock Announced: US$50M · US$3 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), J.P. Morgan (co-lead), Jefferies (co-lead), TD Cowen (co-lead), TD Securities (USA) LLC (co-lead) Use of proceeds: Advancing internally developed programs, investment in its Integrated Drug Creation platform, working capital and general corporate purposes | Jul 24, 2025 |
| Strategic investment of equity (PIPE) Announced: US$20M Buyers: AMD ($20 million investment) | Jan 8, 2025 |